Dry Age-Related Macular Degeneration Market Size, Top Share, Forecast to 2033

Table Of Content

Executive Summary

Research Scope & Segmentation

Research Objectives
Limitations & Assumptions
Market Scope & Segmentation
Currency & Pricing Considered

Market Opportunity Assessment

Emerging Regions / Countries
Emerging Companies
Emerging Applications / End Use

Market Trends

Drivers
Market Warning Factors
Latest Macro Economic Indicators
Geopolitical Impact
Technology Factors

Market Assessment

Porters Five Forces Analysis
Value Chain Analysis

Regulatory Framework

North America
Europe
APAC
Middle East and Africa
LATAM

ESG Trends

Global Dry Age-Related Macular Degeneration Market Size Analysis

Global Dry Age-Related Macular Degeneration Market Introduction
By Stage
1. Introduction
  1. Stage By Value
2. Early Age-Related Macular Degeneration
  1. By Value
3. Intermediate Age-Related Macular Degeneration
  1. By Value
4. Late Age-Related Macular Degeneration
  1. By Value
By Age Group
1. Introduction
  1. Age Group By Value
2. Above 75 Years
  1. By Value
3. Above 60 Years
  1. By Value
4. Above 40 Years
  1. By Value
By Route of Administration
1. Introduction
  1. Route of Administration By Value
2. Oral
  1. By Value
3. Injectable
  1. By Value
By Distribution Channel
1. Introduction
  1. Distribution Channel By Value
2. Hospital Pharmacies
  1. By Value
3. Drug Stores and Retail Pharmacies
  1. By Value
4. Online Pharmacies
  1. By Value

North America Market Analysis

Introduction
By Stage
1. Introduction
  1. Stage By Value
2. Early Age-Related Macular Degeneration
  1. By Value
3. Intermediate Age-Related Macular Degeneration
  1. By Value
4. Late Age-Related Macular Degeneration
  1. By Value
By Age Group
1. Introduction
  1. Age Group By Value
2. Above 75 Years
  1. By Value
3. Above 60 Years
  1. By Value
4. Above 40 Years
  1. By Value
By Route of Administration
1. Introduction
  1. Route of Administration By Value
2. Oral
  1. By Value
3. Injectable
  1. By Value
By Distribution Channel
1. Introduction
  1. Distribution Channel By Value
2. Hospital Pharmacies
  1. By Value
3. Drug Stores and Retail Pharmacies
  1. By Value
4. Online Pharmacies
  1. By Value
U.S.
1. By Stage
  1. Introduction
    1. Stage By Value
  2. Early Age-Related Macular Degeneration
    1. By Value
  3. Intermediate Age-Related Macular Degeneration
    1. By Value
  4. Late Age-Related Macular Degeneration
    1. By Value
2. By Age Group
  1. Introduction
    1. Age Group By Value
  2. Above 75 Years
    1. By Value
  3. Above 60 Years
    1. By Value
  4. Above 40 Years
    1. By Value
3. By Route of Administration
  1. Introduction
    1. Route of Administration By Value
  2. Oral
    1. By Value
  3. Injectable
    1. By Value
4. By Distribution Channel
  1. Introduction
    1. Distribution Channel By Value
  2. Hospital Pharmacies
    1. By Value
  3. Drug Stores and Retail Pharmacies
    1. By Value
  4. Online Pharmacies
    1. By Value
Canada

Europe Market Analysis

Introduction
By Stage
1. Introduction
  1. Stage By Value
2. Early Age-Related Macular Degeneration
  1. By Value
3. Intermediate Age-Related Macular Degeneration
  1. By Value
4. Late Age-Related Macular Degeneration
  1. By Value
By Age Group
1. Introduction
  1. Age Group By Value
2. Above 75 Years
  1. By Value
3. Above 60 Years
  1. By Value
4. Above 40 Years
  1. By Value
By Route of Administration
1. Introduction
  1. Route of Administration By Value
2. Oral
  1. By Value
3. Injectable
  1. By Value
By Distribution Channel
1. Introduction
  1. Distribution Channel By Value
2. Hospital Pharmacies
  1. By Value
3. Drug Stores and Retail Pharmacies
  1. By Value
4. Online Pharmacies
  1. By Value
U.K.
1. By Stage
  1. Introduction
    1. Stage By Value
  2. Early Age-Related Macular Degeneration
    1. By Value
  3. Intermediate Age-Related Macular Degeneration
    1. By Value
  4. Late Age-Related Macular Degeneration
    1. By Value
2. By Age Group
  1. Introduction
    1. Age Group By Value
  2. Above 75 Years
    1. By Value
  3. Above 60 Years
    1. By Value
  4. Above 40 Years
    1. By Value
3. By Route of Administration
  1. Introduction
    1. Route of Administration By Value
  2. Oral
    1. By Value
  3. Injectable
    1. By Value
4. By Distribution Channel
  1. Introduction
    1. Distribution Channel By Value
  2. Hospital Pharmacies
    1. By Value
  3. Drug Stores and Retail Pharmacies
    1. By Value
  4. Online Pharmacies
    1. By Value
Germany
France
Spain
Italy
Russia
Nordic
Benelux
Rest of Europe

APAC Market Analysis

Introduction
By Stage
1. Introduction
  1. Stage By Value
2. Early Age-Related Macular Degeneration
  1. By Value
3. Intermediate Age-Related Macular Degeneration
  1. By Value
4. Late Age-Related Macular Degeneration
  1. By Value
By Age Group
1. Introduction
  1. Age Group By Value
2. Above 75 Years
  1. By Value
3. Above 60 Years
  1. By Value
4. Above 40 Years
  1. By Value
By Route of Administration
1. Introduction
  1. Route of Administration By Value
2. Oral
  1. By Value
3. Injectable
  1. By Value
By Distribution Channel
1. Introduction
  1. Distribution Channel By Value
2. Hospital Pharmacies
  1. By Value
3. Drug Stores and Retail Pharmacies
  1. By Value
4. Online Pharmacies
  1. By Value
China
1. By Stage
  1. Introduction
    1. Stage By Value
  2. Early Age-Related Macular Degeneration
    1. By Value
  3. Intermediate Age-Related Macular Degeneration
    1. By Value
  4. Late Age-Related Macular Degeneration
    1. By Value
2. By Age Group
  1. Introduction
    1. Age Group By Value
  2. Above 75 Years
    1. By Value
  3. Above 60 Years
    1. By Value
  4. Above 40 Years
    1. By Value
3. By Route of Administration
  1. Introduction
    1. Route of Administration By Value
  2. Oral
    1. By Value
  3. Injectable
    1. By Value
4. By Distribution Channel
  1. Introduction
    1. Distribution Channel By Value
  2. Hospital Pharmacies
    1. By Value
  3. Drug Stores and Retail Pharmacies
    1. By Value
  4. Online Pharmacies
    1. By Value
Korea
Japan
India
Australia
Taiwan
South East Asia
Rest of Asia-Pacific

Middle East and Africa Market Analysis

Introduction
By Stage
1. Introduction
  1. Stage By Value
2. Early Age-Related Macular Degeneration
  1. By Value
3. Intermediate Age-Related Macular Degeneration
  1. By Value
4. Late Age-Related Macular Degeneration
  1. By Value
By Age Group
1. Introduction
  1. Age Group By Value
2. Above 75 Years
  1. By Value
3. Above 60 Years
  1. By Value
4. Above 40 Years
  1. By Value
By Route of Administration
1. Introduction
  1. Route of Administration By Value
2. Oral
  1. By Value
3. Injectable
  1. By Value
By Distribution Channel
1. Introduction
  1. Distribution Channel By Value
2. Hospital Pharmacies
  1. By Value
3. Drug Stores and Retail Pharmacies
  1. By Value
4. Online Pharmacies
  1. By Value
UAE
1. By Stage
  1. Introduction
    1. Stage By Value
  2. Early Age-Related Macular Degeneration
    1. By Value
  3. Intermediate Age-Related Macular Degeneration
    1. By Value
  4. Late Age-Related Macular Degeneration
    1. By Value
2. By Age Group
  1. Introduction
    1. Age Group By Value
  2. Above 75 Years
    1. By Value
  3. Above 60 Years
    1. By Value
  4. Above 40 Years
    1. By Value
3. By Route of Administration
  1. Introduction
    1. Route of Administration By Value
  2. Oral
    1. By Value
  3. Injectable
    1. By Value
4. By Distribution Channel
  1. Introduction
    1. Distribution Channel By Value
  2. Hospital Pharmacies
    1. By Value
  3. Drug Stores and Retail Pharmacies
    1. By Value
  4. Online Pharmacies
    1. By Value
Turkey
Saudi Arabia
South Africa
Egypt
Nigeria
Rest of MEA

LATAM Market Analysis

Introduction
By Stage
1. Introduction
  1. Stage By Value
2. Early Age-Related Macular Degeneration
  1. By Value
3. Intermediate Age-Related Macular Degeneration
  1. By Value
4. Late Age-Related Macular Degeneration
  1. By Value
By Age Group
1. Introduction
  1. Age Group By Value
2. Above 75 Years
  1. By Value
3. Above 60 Years
  1. By Value
4. Above 40 Years
  1. By Value
By Route of Administration
1. Introduction
  1. Route of Administration By Value
2. Oral
  1. By Value
3. Injectable
  1. By Value
By Distribution Channel
1. Introduction
  1. Distribution Channel By Value
2. Hospital Pharmacies
  1. By Value
3. Drug Stores and Retail Pharmacies
  1. By Value
4. Online Pharmacies
  1. By Value
Brazil
1. By Stage
  1. Introduction
    1. Stage By Value
  2. Early Age-Related Macular Degeneration
    1. By Value
  3. Intermediate Age-Related Macular Degeneration
    1. By Value
  4. Late Age-Related Macular Degeneration
    1. By Value
2. By Age Group
  1. Introduction
    1. Age Group By Value
  2. Above 75 Years
    1. By Value
  3. Above 60 Years
    1. By Value
  4. Above 40 Years
    1. By Value
3. By Route of Administration
  1. Introduction
    1. Route of Administration By Value
  2. Oral
    1. By Value
  3. Injectable
    1. By Value
4. By Distribution Channel
  1. Introduction
    1. Distribution Channel By Value
  2. Hospital Pharmacies
    1. By Value
  3. Drug Stores and Retail Pharmacies
    1. By Value
  4. Online Pharmacies
    1. By Value
Mexico
Argentina
Chile
Colombia
Rest of LATAM

Competitive Landscape

Dry Age-Related Macular Degeneration Market Share By Players
M&A Agreements & Collaboration Analysis

Market Players Assessment

Apellis Pharmaceuticals, Inc
1. Overview
2. Business Information
3. Revenue
4. ASP
5. SWOT Analysis
6. Recent Developments
Astellas Pharma Inc. (Iveric Bio)
Hoffmann-La Roche AG (Genentech, Inc.)
Disc Medicine, Inc. (Gemini Therapeutics, Inc.)
Ionis Pharmaceuticals
NGM Biopharmaceuticals
Annexon Biosciences
AstraZeneca (Alexion Pharmaceuticals)
Boehringer Ingelheim
ONL Therapeutics
Biogen
Novartis AG
Stealth Biotherapeutics Corp.

Research Methodology

Research Data
1. Secondary Data
  1. Major secondary sources
  2. Key data from secondary sources
2. Primary Data
  1. Key data from primary sources
  2. Breakdown of primaries
3. Secondary And Primary Research
  1. Key industry insights
Market Size Estimation
1. Bottom-Up Approach
2. Top-Down Approach
3. Market Projection
Research Assumptions
1. Assumptions
Limitations
Risk Assessment